This compound stabilizes p53 and activates its pathway, resulting in the interruption of the cell proliferation, cell cycle arrest and apoptosis, and is currently in phase I clinical trials for cancer treatment [122,123,124,125]. The gene discussed is TP53; the disease is cancer.